Lauren M. Byrne

Lauren M. Byrne

Auto-generated profile, based on publicly available information

Lauren M. Byrne

Huntington’s Disease Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LBLauren M. Byrne
Lauren M. Byrne
FRFilipe Brogueira Rodrigues
Filipe Brogueira Rodrigues
EJEileanor B. Johnson
Eileanor B. Johnson
PWPeter A. Wijeratne
Peter A. Wijeratne
EVEnrico De Vita
Enrico De Vita
EWEdward Wild
Edward Wild
Huntington’s disease (HD) is a genetic progressive neurodegenerative disorder, caused by a mutation in the HTT gene, for which there is currently no cure. The identification of sensitive indicators of disease progression and therapeutic outcome could help the development of effective strategies for treating HD. We assessed mutant huntingtin (mHTT) and neurofilament light (NfL) protein concentrations in cerebrospinal fluid (CSF) and blood in parallel with clinical evaluation and magnetic resonance imaging in premanifest and manifest HD mutation carriers. Among HD mutation carriers, NfL concentrations in plasma and CSF correlated with all nonbiofluid measures more closely than did CSF mHTT concentration. Longitudinal analysis over 4 to 8 weeks showed that CSF mHTT, CSF NfL, and plasma NfL concentrations were highly stable within individuals. In our cohort, concentration of CSF mHTT accurately distinguished between controls and HD mutation carriers, whereas NfL concentration, in both CSF and plasma, was able to segregate premanifest from manifest HD. In silico modeling indicated that mHTT and NfL concentrations in biofluids might be among the earliest detectable alterations in HD, and sample size prediction suggested that low participant numbers would be needed to incorporate these measures into clinical trials. These findings provide evidence that biofluid concentrations of mHTT and NfL have potential for early and sensitive detection of alterations in HD and could be integrated into both clinical trials and the clinic.

16 December 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FRFilipe Brogueira Rodrigues
Filipe Brogueira Rodrigues
LBLauren M. Byrne
Lauren M. Byrne
RTRosanna Tortelli
Rosanna Tortelli
EJEileanoir B. Johnson
Eileanoir B. Johnson
PWPeter Wijeratne
Peter Wijeratne
EWEdward Wild
Edward Wild
Longitudinal analysis in 80 patients shows that mutant huntingtin and neurofilament light could predict Huntington’s disease progression.

15 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ISIsabella I. Sanchez
Isabella I. Sanchez
TNThai B. Nguyen
Thai B. Nguyen
WEWhitney E. England
Whitney E. England
RLRyan G. Lim
Ryan G. Lim
AVAnthony Q. Vu
Anthony Q. Vu
LTLeslie M. Thompson
Leslie M. Thompson
Chronic cellular stress associated with neurodegenerative disease can result in the persistence of stress granule (SG) structures, membraneless organelles that form in response to cellular stress. In Huntington’s disease (HD), chronic expression of mutant huntingtin generates various forms of cellular stress, including activation of the unfolded protein response and oxidative stress. However, it has yet to be determined whether SGs are a feature of HD neuropathology. We examined the miRNA composition of extracellular vesicles (EVs) present in the cerebrospinal fluid (CSF) of patients with HD and show that a subset of their target mRNAs were differentially expressed in the prefrontal cortex. Of these targets, SG components were enriched, including the SG-nucleating Ras GTPase-activating protein-binding protein 1 (G3BP1). We investigated localization and levels of G3BP1 and found a significant increase in the density of G3BP1-positive granules in the cortex and hippocampus of R6/2 transgenic mice and in the superior frontal cortex of the brains of patients with HD. Intriguingly, we also observed that the SG-associated TAR DNA-binding protein 43 (TDP43), a nuclear RNA/DNA binding protein, was mislocalized to the cytoplasm of G3BP1 granule–positive HD cortical neurons. These findings suggest that G3BP1 SG dynamics may play a role in the pathophysiology of HD.

28 June 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
FLFlorian Lipsmeier
Florian Lipsmeier
CSCedric Simillion
Cedric Simillion
ABAtieh Bamdadian
Atieh Bamdadian
RTRosanna Tortelli
Rosanna Tortelli
LBLauren M Byrne
Lauren M Byrne
MLMichael Lindemann
Michael Lindemann
Background: Remote monitoring of Huntington disease (HD) signs and symptoms using digital technologies may enhance early clinical diagnosis and tracking of disease progression, guide treatment decisions, and monitor response to disease-modifying agents. Several recent studies in neurodegenerative diseases have demonstrated the feasibility of digital symptom monitoring. Objective: The aim of this study was to evaluate a novel smartwatch- and smartphone-based digital monitoring platform to remotely monitor signs and symptoms of HD. Methods: This analysis aimed to determine the feasibility and reliability of the Roche HD Digital Monitoring Platform over a 4-week period and cross-sectional validity over a 2-week interval. Key criteria assessed were feasibility, evaluated by adherence and quality control failure rates; test-retest reliability; known-groups validity; and convergent validity of sensor-based measures with existing clinical measures. Data from 3 studies were used: the predrug screening phase of an open-label extension study evaluating tominersen (NCT03342053) and 2 untreated cohorts—the HD Natural History Study (NCT03664804) and the Digital-HD study. Across these studies, controls (n=20) and individuals with premanifest (n=20) or manifest (n=179) HD completed 6 motor and 2 cognitive tests at home and in the clinic. Results: Participants in the open-label extension study, the HD Natural History Study, and the Digital-HD study completed 89.95% (1164/1294), 72.01% (2025/2812), and 68.98% (1454/2108) of the active tests, respectively. All sensor-based features showed good to excellent test-retest reliability (intraclass correlation coefficient 0.89-0.98) and generally low quality control failure rates. Good overall convergent validity of sensor-derived features to Unified HD Rating Scale outcomes and good overall known-groups validity among controls, premanifest, and manifest participants were observed. Among participants with manifest HD, the digital cognitive tests demonstrated the strongest correlations with analogous in-clinic tests (Pearson correlation coefficient 0.79-0.90). Conclusions: These results show the potential of the HD Digital Monitoring Platform to provide reliable, valid, continuous remote monitoring of HD symptoms, facilitating the evaluation of novel treatments and enhanced clinical monitoring and care for individuals with HD.

18 April 2022 in Movement Disorders
Verified
Journal Article
Open access
LBLauren M. Byrne
Lauren M. Byrne
JSJordan Schultz
Jordan Schultz
FRFilipe Brogueira Rodrigues
Filipe Brogueira Rodrigues
Ellen Van Der PlasEllen Van Der Plas
Ellen Van Der Plas
DLDouglas Langbehn
Douglas Langbehn
EWEdward Wild
Edward Wild
Background: Juvenile‐onset Huntington's disease (JOHD) is a rare and particularly devastating form of Huntington's disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking. Neurofilament light protein (NfL) in plasma has emerged as a prognostic biomarker for adult‐onset HD.Methods: We performed a retrospective analysis of samples and data collected between 2009 and 2020 from the Kids‐HD and Kids‐JHD studies. Plasma samples from children and young adults with JOHD, premanifest HD (preHD) mutation carriers, and age‐matched controls were used to quantify plasma NfL concentrations using ultrasensitive immunoassay.Results: We report elevated plasma NfL concentrations in JOHD and premanifest HD mutation‐carrying children. In pediatric HD mutation carriers who were within 20 years of their predicted onset and patients with JOHD, plasma NfL level was associated with caudate and putamen volumes.Conclusions: Quantifying plasma NfL concentration may assist clinical diagnosis and therapeutic trial design in the pediatric population. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

27 September 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
TMTamara Maiuri
Tamara Maiuri
CBCarlos Barba Bazan
Carlos Barba Bazan
RHRachel Harding
Rachel Harding
NBNola Begeja
Nola Begeja
TKTae-In Kam
Tae-In Kam
RTRay Truant
Ray Truant
Huntington disease (HD) is a genetic neurodegenerative disease caused by cytosine, adenine, guanine (CAG) expansion in the Huntingtin ( HTT ) gene, translating to an expanded polyglutamine tract in the HTT protein. Age at disease onset correlates to CAG repeat length but varies by decades between individuals with identical repeat lengths. Genome-wide association studies link HD modification to DNA repair and mitochondrial health pathways. Clinical studies show elevated DNA damage in HD, even at the premanifest stage. A major DNA repair node influencing neurodegenerative disease is the PARP pathway. Accumulation of poly adenosine diphosphate (ADP)-ribose (PAR) has been implicated in Alzheimer and Parkinson diseases, as well as cerebellar ataxia. We report that HD mutation carriers have lower cerebrospinal fluid PAR levels than healthy controls, starting at the premanifest stage. Human HD induced pluripotent stem cell-derived neurons and patient-derived fibroblasts have diminished PAR response in the context of elevated DNA damage. We have defined a PAR-binding motif in HTT, detected HTT complexed with PARylated proteins in human cells during stress, and localized HTT to mitotic chromosomes upon inhibition of PAR degradation. Direct HTT PAR binding was measured by fluorescence polarization and visualized by atomic force microscopy at the single molecule level. While wild-type and mutant HTT did not differ in their PAR binding ability, purified wild-type HTT protein increased in vitro PARP1 activity while mutant HTT did not. These results provide insight into an early molecular mechanism of HD, suggesting possible targets for the design of early preventive therapies.